Compare Crispr Therapeutics AG (CRSP) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vanguard Total International Stock Index Fund ETF — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.17B), while Vanguard Total International Stock Index Fund ETF trades at $86.99. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | VXUS | |
|---|---|---|
Market Cap | $5.17B | — |
Sector | Health | Sector/Thematic |
52-Week High | $76.78 | $87.21 |
52-Week Low | $44.34 | $70.22 |
Enterprise Value | $3.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
VXUS trades at $87.21, up 1.03% with strong bullish technical signals from moving averages. The ETF offers broad international diversification with over 8,700 non-U.S. stocks, recently delivering 27.82% total returns over the past year according to Seeking Alpha (August 8, 2026). Institutional interest is growing with multiple firms increasing positions, while analysts highlight its valuation discount to U.S. equities.
The outlook remains positive given international diversification benefits and institutional accumulation, though RSI levels suggest potential near-term consolidation. Key risks include global economic volatility and currency fluctuations. Wall Street sentiment leans bullish with Seeking Alpha maintaining a Buy rating, supported by the ETF's low expense ratio and comprehensive market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
